Omalizumab to Treat Eosinophilic Gastroenteritis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 2, 2004

Study Completion Date

February 5, 2007

Conditions

Gastroenteritis

Interventions

DRUG

Omalizumab

Trial Locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00084097 - Omalizumab to Treat Eosinophilic Gastroenteritis | Biotech Hunter | Biotech Hunter